Progressive massive fibrosis: An overview of the recent literature

This review provides an overview of literature addressing progressive massive fibrosis (PMF) from September 2009 to the present. Advances are described in understanding its pathophysiology, epidemiology of the occurrence of PMF and related conditions, the impact of PMF on pulmonary function, advance...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacology & therapeutics (Oxford) 2022-12, Vol.240, p.108232-108232, Article 108232
1. Verfasser: Weissman, David N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 108232
container_issue
container_start_page 108232
container_title Pharmacology & therapeutics (Oxford)
container_volume 240
creator Weissman, David N.
description This review provides an overview of literature addressing progressive massive fibrosis (PMF) from September 2009 to the present. Advances are described in understanding its pathophysiology, epidemiology of the occurrence of PMF and related conditions, the impact of PMF on pulmonary function, advances in imaging of PMF, and factors affecting progression of pneumoconiosis in dust-exposed workers to PMF. Basic advances in understanding the etiology of PMF are impeded by the lack of a well-accepted animal model for human PMF. Recent studies evaluating lung tissue samples and epidemiologic investigations support an important role for the silica component of coal mine dust in causing coal workers' pneumoconiosis and PMF in contemporary coal miners in the United States and for silica in causing silicosis and PMF in artificial stone workers throughout the world. Development of PMF is associated with substantial decline in pulmonary function relative to no disease or small opacity pneumoconiosis. In recent reports, computed tomography has had greater sensitivity for detecting PMF than chest x-ray. Magnetic resonance imaging shows promise in differentiating between PMF and lung cancer. Although PMF develops in dust-exposed workers without previously identified small opacity pneumoconiosis, the presence of small opacity pneumoconiosis increases the risk for progression to PMF, as does heavier dust exposure. Recent literature does not document any effective new treatments for PMF and new therapies to prevent and treat PMF are an important need.
doi_str_mv 10.1016/j.pharmthera.2022.108232
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10053429</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163725822001267</els_id><sourcerecordid>2680238834</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-bc06d8d8e457e8caf1a21f62769300ccdb58c8f4d5566cb5ab8dc44aae502dc3</originalsourceid><addsrcrecordid>eNqFUctOwzAQtBAIyuMXUI5cUhw_EpcLaiteEhIceuBmOfamdZXExU6L-HtcpRQ4cRppd3ZmNYNQkuFhhrP8ejlcLZRvugV4NSSYkDgWhJIDNMhEMUoj5-0QDSLQtCBcnKDTEJYYY8YwOUYnlBeUEFYM0OTVu7mHEOwGkkb1WNnSu2DDTTJuE7cBv7HwkbgqiYaJBw1tl9S2i-bd2sM5OqpUHeBih2dodn83mz6mzy8PT9Pxc6ppjru01Dg3wghgvAChVZUpklU5KfIRxVhrU3KhRcUM53muS65KYTRjSgHHxGh6hm572dW6bMBsn_CqlitvG-U_pVNW_t20diHnbiMzjDllZBQVrnYK3r2vIXSysUFDXasW3DpIkgtMqBCURaroqToGETxUe58My20Fcil_KpDbCmRfQTy9_P3n_vA780iY9ASIYcVkvQzaQqvB2JhtJ42z_7t8AS_Yn2A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2680238834</pqid></control><display><type>article</type><title>Progressive massive fibrosis: An overview of the recent literature</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Weissman, David N.</creator><creatorcontrib>Weissman, David N.</creatorcontrib><description>This review provides an overview of literature addressing progressive massive fibrosis (PMF) from September 2009 to the present. Advances are described in understanding its pathophysiology, epidemiology of the occurrence of PMF and related conditions, the impact of PMF on pulmonary function, advances in imaging of PMF, and factors affecting progression of pneumoconiosis in dust-exposed workers to PMF. Basic advances in understanding the etiology of PMF are impeded by the lack of a well-accepted animal model for human PMF. Recent studies evaluating lung tissue samples and epidemiologic investigations support an important role for the silica component of coal mine dust in causing coal workers' pneumoconiosis and PMF in contemporary coal miners in the United States and for silica in causing silicosis and PMF in artificial stone workers throughout the world. Development of PMF is associated with substantial decline in pulmonary function relative to no disease or small opacity pneumoconiosis. In recent reports, computed tomography has had greater sensitivity for detecting PMF than chest x-ray. Magnetic resonance imaging shows promise in differentiating between PMF and lung cancer. Although PMF develops in dust-exposed workers without previously identified small opacity pneumoconiosis, the presence of small opacity pneumoconiosis increases the risk for progression to PMF, as does heavier dust exposure. Recent literature does not document any effective new treatments for PMF and new therapies to prevent and treat PMF are an important need.</description><identifier>ISSN: 0163-7258</identifier><identifier>EISSN: 1879-016X</identifier><identifier>DOI: 10.1016/j.pharmthera.2022.108232</identifier><identifier>PMID: 35732247</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Anthracosis - complications ; Anthracosis - epidemiology ; Antifibrotic ; Chest imaging ; Coal ; Coal Mining ; Coal workers' pneumoconiosis ; Dust ; Fibrosis ; Humans ; Pneumoconiosis - diagnostic imaging ; Pneumoconiosis - epidemiology ; Pneumoconiosis - etiology ; Progressive massive fibrosis ; Pulmonary function ; Silicon Dioxide ; Silicosis ; United States</subject><ispartof>Pharmacology &amp; therapeutics (Oxford), 2022-12, Vol.240, p.108232-108232, Article 108232</ispartof><rights>2022</rights><rights>Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-bc06d8d8e457e8caf1a21f62769300ccdb58c8f4d5566cb5ab8dc44aae502dc3</citedby><cites>FETCH-LOGICAL-c360t-bc06d8d8e457e8caf1a21f62769300ccdb58c8f4d5566cb5ab8dc44aae502dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0163725822001267$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35732247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weissman, David N.</creatorcontrib><title>Progressive massive fibrosis: An overview of the recent literature</title><title>Pharmacology &amp; therapeutics (Oxford)</title><addtitle>Pharmacol Ther</addtitle><description>This review provides an overview of literature addressing progressive massive fibrosis (PMF) from September 2009 to the present. Advances are described in understanding its pathophysiology, epidemiology of the occurrence of PMF and related conditions, the impact of PMF on pulmonary function, advances in imaging of PMF, and factors affecting progression of pneumoconiosis in dust-exposed workers to PMF. Basic advances in understanding the etiology of PMF are impeded by the lack of a well-accepted animal model for human PMF. Recent studies evaluating lung tissue samples and epidemiologic investigations support an important role for the silica component of coal mine dust in causing coal workers' pneumoconiosis and PMF in contemporary coal miners in the United States and for silica in causing silicosis and PMF in artificial stone workers throughout the world. Development of PMF is associated with substantial decline in pulmonary function relative to no disease or small opacity pneumoconiosis. In recent reports, computed tomography has had greater sensitivity for detecting PMF than chest x-ray. Magnetic resonance imaging shows promise in differentiating between PMF and lung cancer. Although PMF develops in dust-exposed workers without previously identified small opacity pneumoconiosis, the presence of small opacity pneumoconiosis increases the risk for progression to PMF, as does heavier dust exposure. Recent literature does not document any effective new treatments for PMF and new therapies to prevent and treat PMF are an important need.</description><subject>Anthracosis - complications</subject><subject>Anthracosis - epidemiology</subject><subject>Antifibrotic</subject><subject>Chest imaging</subject><subject>Coal</subject><subject>Coal Mining</subject><subject>Coal workers' pneumoconiosis</subject><subject>Dust</subject><subject>Fibrosis</subject><subject>Humans</subject><subject>Pneumoconiosis - diagnostic imaging</subject><subject>Pneumoconiosis - epidemiology</subject><subject>Pneumoconiosis - etiology</subject><subject>Progressive massive fibrosis</subject><subject>Pulmonary function</subject><subject>Silicon Dioxide</subject><subject>Silicosis</subject><subject>United States</subject><issn>0163-7258</issn><issn>1879-016X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUctOwzAQtBAIyuMXUI5cUhw_EpcLaiteEhIceuBmOfamdZXExU6L-HtcpRQ4cRppd3ZmNYNQkuFhhrP8ejlcLZRvugV4NSSYkDgWhJIDNMhEMUoj5-0QDSLQtCBcnKDTEJYYY8YwOUYnlBeUEFYM0OTVu7mHEOwGkkb1WNnSu2DDTTJuE7cBv7HwkbgqiYaJBw1tl9S2i-bd2sM5OqpUHeBih2dodn83mz6mzy8PT9Pxc6ppjru01Dg3wghgvAChVZUpklU5KfIRxVhrU3KhRcUM53muS65KYTRjSgHHxGh6hm572dW6bMBsn_CqlitvG-U_pVNW_t20diHnbiMzjDllZBQVrnYK3r2vIXSysUFDXasW3DpIkgtMqBCURaroqToGETxUe58My20Fcil_KpDbCmRfQTy9_P3n_vA780iY9ASIYcVkvQzaQqvB2JhtJ42z_7t8AS_Yn2A</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Weissman, David N.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221201</creationdate><title>Progressive massive fibrosis: An overview of the recent literature</title><author>Weissman, David N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-bc06d8d8e457e8caf1a21f62769300ccdb58c8f4d5566cb5ab8dc44aae502dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anthracosis - complications</topic><topic>Anthracosis - epidemiology</topic><topic>Antifibrotic</topic><topic>Chest imaging</topic><topic>Coal</topic><topic>Coal Mining</topic><topic>Coal workers' pneumoconiosis</topic><topic>Dust</topic><topic>Fibrosis</topic><topic>Humans</topic><topic>Pneumoconiosis - diagnostic imaging</topic><topic>Pneumoconiosis - epidemiology</topic><topic>Pneumoconiosis - etiology</topic><topic>Progressive massive fibrosis</topic><topic>Pulmonary function</topic><topic>Silicon Dioxide</topic><topic>Silicosis</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weissman, David N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pharmacology &amp; therapeutics (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weissman, David N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progressive massive fibrosis: An overview of the recent literature</atitle><jtitle>Pharmacology &amp; therapeutics (Oxford)</jtitle><addtitle>Pharmacol Ther</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>240</volume><spage>108232</spage><epage>108232</epage><pages>108232-108232</pages><artnum>108232</artnum><issn>0163-7258</issn><eissn>1879-016X</eissn><abstract>This review provides an overview of literature addressing progressive massive fibrosis (PMF) from September 2009 to the present. Advances are described in understanding its pathophysiology, epidemiology of the occurrence of PMF and related conditions, the impact of PMF on pulmonary function, advances in imaging of PMF, and factors affecting progression of pneumoconiosis in dust-exposed workers to PMF. Basic advances in understanding the etiology of PMF are impeded by the lack of a well-accepted animal model for human PMF. Recent studies evaluating lung tissue samples and epidemiologic investigations support an important role for the silica component of coal mine dust in causing coal workers' pneumoconiosis and PMF in contemporary coal miners in the United States and for silica in causing silicosis and PMF in artificial stone workers throughout the world. Development of PMF is associated with substantial decline in pulmonary function relative to no disease or small opacity pneumoconiosis. In recent reports, computed tomography has had greater sensitivity for detecting PMF than chest x-ray. Magnetic resonance imaging shows promise in differentiating between PMF and lung cancer. Although PMF develops in dust-exposed workers without previously identified small opacity pneumoconiosis, the presence of small opacity pneumoconiosis increases the risk for progression to PMF, as does heavier dust exposure. Recent literature does not document any effective new treatments for PMF and new therapies to prevent and treat PMF are an important need.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>35732247</pmid><doi>10.1016/j.pharmthera.2022.108232</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0163-7258
ispartof Pharmacology & therapeutics (Oxford), 2022-12, Vol.240, p.108232-108232, Article 108232
issn 0163-7258
1879-016X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10053429
source MEDLINE; Elsevier ScienceDirect Journals
subjects Anthracosis - complications
Anthracosis - epidemiology
Antifibrotic
Chest imaging
Coal
Coal Mining
Coal workers' pneumoconiosis
Dust
Fibrosis
Humans
Pneumoconiosis - diagnostic imaging
Pneumoconiosis - epidemiology
Pneumoconiosis - etiology
Progressive massive fibrosis
Pulmonary function
Silicon Dioxide
Silicosis
United States
title Progressive massive fibrosis: An overview of the recent literature
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T17%3A36%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progressive%20massive%20fibrosis:%20An%20overview%20of%20the%20recent%20literature&rft.jtitle=Pharmacology%20&%20therapeutics%20(Oxford)&rft.au=Weissman,%20David%20N.&rft.date=2022-12-01&rft.volume=240&rft.spage=108232&rft.epage=108232&rft.pages=108232-108232&rft.artnum=108232&rft.issn=0163-7258&rft.eissn=1879-016X&rft_id=info:doi/10.1016/j.pharmthera.2022.108232&rft_dat=%3Cproquest_pubme%3E2680238834%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2680238834&rft_id=info:pmid/35732247&rft_els_id=S0163725822001267&rfr_iscdi=true